These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 2541126)

  • 1. The antiviral activity of dideoxycytidine.
    Jeffries DJ
    J Antimicrob Chemother; 1989 Jan; 23 Suppl A():29-34. PubMed ID: 2541126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human immunodeficiency virus inhibition is prolonged by 3'-azido-3'-deoxythymidine alternating with 2',3'-dideoxycytidine compared with 3'-azido-3'-deoxythymidine alone.
    Spector SA; Ripley D; Hsia K
    Antimicrob Agents Chemother; 1989 Jun; 33(6):920-3. PubMed ID: 2548440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides.
    Perno CF; Yarchoan R; Cooney DA; Hartman NR; Gartner S; Popovic M; Hao Z; Gerrard TL; Wilson YA; Johns DG
    J Exp Med; 1988 Sep; 168(3):1111-25. PubMed ID: 2844951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic evaluation of drug interactions with anti-human immunotrophic virus (HIV) Drugs. III. 2',3'-Dideoxycytidine (ddC) and zidovudine in monkeys.
    Qian MX; Swagler AR; Mehta M; Vishwanathan CT; Gallo JM
    Pharm Res; 1992 Feb; 9(2):224-7. PubMed ID: 1313173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of stereochemistry on antiviral activities and resistance profiles of dideoxycytidine nucleosides.
    Van Draanen NA; Tisdale M; Parry NR; Jansen R; Dornsife RE; Tuttle JV; Averett DR; Koszalka GW
    Antimicrob Agents Chemother; 1994 Apr; 38(4):868-71. PubMed ID: 7518218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased anti-human immunodeficiency virus type-1 activities of 2',3'-dideoxynucleoside analogs in MOLT-4 cell sublines resistant to 2',3'-dideoxynucleoside analogs.
    Cinatl J; Cinatl J; Weber B; Rabenau H; Weissflog A; Mainke M; Kornhuber B; Doerr HW
    Acta Virol; 1993 Oct; 37(5):360-8. PubMed ID: 8184788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2',3'-dideoxycytidine.
    Chen CH; Cheng YC
    J Biol Chem; 1989 Jul; 264(20):11934-7. PubMed ID: 2745424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS and related disorders.
    Klecker RW; Collins JM; Yarchoan RC; Thomas R; McAtee N; Broder S; Myers CE
    J Clin Pharmacol; 1988 Sep; 28(9):837-42. PubMed ID: 2852679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics of 2',3'-dideoxycytidine: an inhibitor of human immunodeficiency virus.
    Broder S
    Am J Med; 1990 May; 88(5B):2S-7S. PubMed ID: 1692446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro antiviral activity of didanosine compared with that of other dideoxynucleoside analogs against laboratory strains and clinical isolates of human immunodeficiency virus.
    Hitchcock MJ
    Clin Infect Dis; 1993 Feb; 16 Suppl 1():S16-21. PubMed ID: 8425017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiviral effects of 3'-azido-3'-deoxythymidine, 2',3'-dideoxycytidine, and 2',3'-dideoxyadenosine against simian acquired immunodeficiency syndrome-associated type D retrovirus in vitro.
    Tsai CC; Follis KE; Benveniste RE
    AIDS Res Hum Retroviruses; 1988 Oct; 4(5):359-68. PubMed ID: 2461724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of human immunodeficiency virus-infected infants and young children with dideoxynucleosides.
    Pizzo PA
    Am J Med; 1990 May; 88(5B):16S-19S. PubMed ID: 2159704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2',3'-dideoxynucleosides.
    Gao WY; Johns DG; Mitsuya H
    Mol Pharmacol; 1994 Oct; 46(4):767-72. PubMed ID: 7969058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro anti-human immunodeficiency virus and anti-hepatitis B virus activities and pharmacokinetic properties of heterodinucleoside phosphates containing AZT or ddC.
    Peghini PA; Zahner R; Kuster H; Schott H; Schwendener RA
    Antivir Chem Chemother; 1998 Mar; 9(2):117-26. PubMed ID: 9875383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dideoxycytidine: current clinical experience and future prospects. A summary.
    Broder S; Yarchoan R
    Am J Med; 1990 May; 88(5B):31S-33S. PubMed ID: 2159708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2',3'-dideoxycytidine, or recombinant interferon-alpha A against zidovudine-sensitive or -resistant HIV-1 in vitro.
    Johnson VA; Merrill DP; Chou TC; Hirsch MS
    J Infect Dis; 1992 Nov; 166(5):1143-6. PubMed ID: 1328402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial clinical experience with dideoxynucleosides as single agents and in combination therapy.
    Yarchoan R; Pluda JM; Perno CF; Mitsuya H; Thomas RV; Wyvill KM; Broder S
    Ann N Y Acad Sci; 1990; 616():328-43. PubMed ID: 2078027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The antiretroviral and cytostatic activity, and metabolism of 3'-azido-2',3'-dideoxythymidine, 3'-fluoro-2',3'-dideoxythymidine and 2',3'-dideoxycytidine are highly cell type-dependent.
    Balzarini J; Matthes E; Meeus P; Johns DG; De Clercq E
    Adv Exp Med Biol; 1989; 253B():407-13. PubMed ID: 2558542
    [No Abstract]   [Full Text] [Related]  

  • 19. [Prospects in the treatment of AIDS. II. AZT and related compounds; practical conclusions].
    Grieb P
    Pol Arch Med Wewn; 1992; 87(4-5):316-23. PubMed ID: 1381825
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacokinetic evaluation of drug interactions with anti-human immunodeficiency virus drugs. V. Effect of soluble CD4 on 2',3'-dideoxycytidine kinetics in monkeys.
    Qian M; Swagler AR; Fong KL; Crysler CS; Mehta M; Gallo JM
    Drug Metab Dispos; 1992; 20(3):396-401. PubMed ID: 1355714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.